Prolactinomas: evolution after menopause
| Autor: | Marisa Servidio, Karina Danilowicz, Natalia García-Basavilbaso, Débora Katz, Maria Carolina Ballarino, Daniel Moncet, Analía Alfieri, Laura Boero, María Susana Mallea-Gil, Mariela Glerean, Patricia Fainstein Day, Marcela Martinez, Sabrina Diez, Marcelo Vitale, Graciela Stalldecker, Alberto Chervin, Amelia Rogozinski, Karina Miragaya, Marcos Manavela, Monica Graciela Loto, Mirtha Guitelman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Adenoma
Adult medicine.medical_specialty Cabergoline Endocrinology Diabetes and Metabolism lcsh:Medicine menopause dopamine agonist 030209 endocrinology & metabolism Pituitary neoplasm Dopamine agonist lcsh:Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Pituitary Neoplasms Prolactinoma Ergolines Bromocriptine Retrospective Studies bromocriptine lcsh:RC648-665 business.industry lcsh:R Middle Aged medicine.disease Prolactin Menopause Endocrinology Treatment Outcome Withholding Treatment 030220 oncology & carcinogenesis Dopamine Agonists Disease Progression cabergoline Female business medicine.drug |
| Zdroj: | Archives of Endocrinology and Metabolism, Volume: 60, Issue: 1, Pages: 42-46, Published: FEB 2016 Archives of Endocrinology and Metabolism v.60 n.1 2016 Arquivos de Endocrinologia e Metabolismo Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM Archives of Endocrinology and Metabolism, Vol 60, Iss 1, Pp 42-46 |
| Popis: | Objetive The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period. Age at menopause was 49 ± 3.6 years. The average time of treatment was 135 ± 79 months. The time of follow-up after treatment suspension was 4 to 192 months. Results Pre-treatment PRL levels in micro and macroadenomas were 119 ± 57 ng/mL and 258 ± 225 ng/mL, respectively. During menopause after treatment suspension, and at the latest follow-up: in microadenomas PRL levels were 23 ± 13 ng/mL and 16 ± 5.7 ng/mL, respectively; in macroadenomas, PRL levels were 20 ± 6.6 ng/mL 5t5and 25 ± 18 ng/mL, respectively. In menopause after treatment suspension, the microadenomas had disappeared in 9/22 and had decreased in 13/22. In the group of patients whose tumor had decreased, in the latest follow-up, tumors disappeared in 7/13 and remained unchanged in 6/13. In macroadenomas, after treatment suspension 3/7 had disappeared, 3/7 decreased and 1/7 remained unchanged. In the latest control in the 3 patients whose tumor decreased, disappeared in 1/3, decreased in 1/3 and there was no change in the remaining. Conclusions Normal PRL levels and sustained reduction or disappearance of adenomas were achieved in most of patients, probably due to the decrease of estrogen levels. Dopamine agonists might be stopped after menopause in patients with prolactinomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|